Tiziana Secures $3.4M in Non-Dilutive Funding

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a biotechnology firm focused on developing innovative therapies for neurodegenerative diseases linked to neuroinflammatory processes, has announced the acquisition of $3.4 million in non-dilutive funding. This financial support will bolster the company's ongoing Phase 2 clinical trial of intranasal foralumab for treating non-active secondary progressive multiple sclerosis (na-SPMS) and its research efforts in Alzheimer’s Disease.

Gabriele Cerrone, Chairman, acting CEO, and founder of Tiziana Life Sciences, expressed satisfaction with the funding, stating that it will support their current studies and hinting at the potential for securing additional non-dilutive funding in the near future.

The company’s primary focus lies with Foralumab, a unique fully human anti-CD3 monoclonal antibody (mAb). Foralumab targets the T cell receptor, effectively reducing inflammation by modulating T cell activity and suppressing the effector functions of various immune cells. This immunomodulatory effect has been observed in patients with COVID-19, multiple sclerosis, and healthy individuals.

The ongoing Phase 2 trial for intranasal foralumab in non-active SPMS began patient screening in November 2023. This innovative approach of administering anti-CD3 mAb via the nasal route offers a promising new treatment pathway for neuroinflammatory and neurodegenerative diseases.

Tiziana Life Sciences is a clinical-stage biopharmaceutical firm that is pioneering transformative drug delivery technologies to create alternative immunotherapy routes. The company's novel nasal delivery method aims to enhance both efficacy and safety compared to traditional intravenous (IV) delivery methods. Intranasal foralumab, Tiziana’s leading candidate, has shown a positive safety profile and clinical response in studies conducted so far.

The company’s patented technology for alternative immunotherapy delivery routes holds significant potential for a wide range of applications within their pipeline.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!